Olatec Therapeutics Adds Parkinson’s Disease Experts
New York, New York, U.S., September 15, 2026 Olatec Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for inflammatory...
Astellas
Advertisement
Astellas PADCEV and Keytruda Gain Positive CHMP Opinion
Tokyo, Japan, September 17, 2026 Astellas Pharma Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products...
Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets
MUMBAI, India & NAPLES, Fla., June 26, 2026 Lupin Limited announced that it has received tentative approval from the...
Gilead Expands Oncology Portfolio With Tubulis Deal
Foster City, California, USA – May 22, 2026 Gilead Sciences, Inc. announced the successful completion of its acquisition of...
Astellas’ PADCEV Combo Wins CHMP Support in MIBC
Tokyo, Japan – May 22, 2026 Astellas Pharma Inc. announced that the European Medicines Agency’s Committee for Medicinal Products...
Advertisements
Renerva Implants First PNM-CAP Device for Neuroma Pain
PITTSBURGH, May 13, 2026 Renerva, Inc. announced the successful first-in-human implantation of its investigational PNM-CAP™ device, marking a major...
Astellas Reports IZERVAY Reduced Vision Decline in GA Patients
NORTHBROOK, Ill., May 12, 2026 Astellas Pharma US announced new clinical findings showing that IZERVAY® (avacincaptad pegol intravitreal solution)...
Dyno AI Capsid Licensed by Astellas for Gene Therapy
WATERTOWN, Mass., April 8, 2026 Dyno Therapeutics, Inc. has announced that Astellas Pharma has exercised its option to license...
Advertisement
